A citation-based method for searching scientific literature

Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore, Andrew J Armstrong, Thomas W Flaig, Aude Fléchon, Paul Mainwaring, Mark Fleming, John D Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S de Bono. N Engl J Med 2012
Times Cited: 3022



Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R Smith. N Engl J Med 2019
Times Cited: 386




List of shared articles



Times cited

Disparities in germline testing among racial minorities with prostate cancer.
Nicole Weise, Justin Shaya, Juan Javier-Desloges, Heather H Cheng, Lisa Madlensky, Rana R McKay. Prostate Cancer Prostatic Dis 2022
3

[Development of a therapeutic education program for prostate cancer patients undergoing new generation hormone therapy].
Alice Cuenant, Isabelle Eglin, Virginia Ferreira, Nadine Houédé. Bull Cancer 2022
0

Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number.
Simon Hawlina, Helena H Chowdhury, Tomaž Smrkolj, Robert Zorec. Biol Direct 2022
0

Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer.
Shiqin Liu, En-Chi Hsu, Michelle Shen, Merve Aslan, Tanya Stoyanova. Methods Mol Biol 2022
0

Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.
Alexander Meisel, Ronald de Wit, Stephane Oudard, Oliver Sartor, Frank Stenner-Liewen, Zhenming Shun, Meredith Foster, Ayse Ozatilgan, Mario Eisenberger, Johann S de Bono. Ther Adv Med Oncol 2022
0

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.
R Kanesvaran, E Castro, A Wong, K Fizazi, M L K Chua, Y Zhu, H Malhotra, Y Miura, J L Lee, F L T Chong,[...]. ESMO Open 2022
0

Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Clement Chung, Karen Abboud. Am J Health Syst Pharm 2022
0

Rational Second-Generation Antiandrogen Use in Prostate Cancer.
Jacob J Orme, Lance C Pagliaro, J Fernando Quevedo, Sean S Park, Brian A Costello. Oncologist 2022
1


Metastatic Prostate Cancer: Treatment Options.
Vérane Achard, Paul Martin Putora, Aurelius Omlin, Thomas Zilli, Stefanie Fischer. Oncology 2022
4

SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Meghan A Rice, Vineet Kumar, Dhanir Tailor, Fernando Jose Garcia-Marques, En-Chi Hsu, Shiqin Liu, Abel Bermudez, Vijayalakshmi Kanchustambham, Vishnu Shankar, Zintis Inde,[...]. Cell Rep Med 2022
2

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer.
Hiroaki Iwamoto, Kouji Izumi, Tomoyuki Makino, Atsushi Mizokami. Cancers (Basel) 2022
1

Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety.
Muhieddine Labban, Marwan Alkassis, Khalid Alkhatib, Logan Briggs, Alexander P Cole, Adam S Kibel, Quoc-Dien Trinh. Urol Clin North Am 2022
1

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.
Yundong He, Weidong Xu, Yu-Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren. Signal Transduct Target Ther 2022
2

Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
Yanhua Chen, Qianqian Zhou, William Hankey, Xiaosheng Fang, Fuwen Yuan. Cell Death Dis 2022
0

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan.
Akira Yokomizo, Junji Yonese, Shin Egawa, Hiroshi Fukuhara, Hiroji Uemura, Kazuo Nishimura, Masayoshi Nagata, Atsushi Saito, Takumi Lee, Susumu Yamaguchi,[...]. Int J Clin Oncol 2022
2